In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Chemotherapy: clinical implications for the heart.

Session Chemotherapy and the heart: what the cardiologist must know

Speaker Johann Bauersachs

Event : ESC Congress 2013

  • Topic : preventive cardiology
  • Sub-topic : Risk Factors and Prevention
  • Session type : Clinical Seminar

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Two columns page  

Chemotherapy and the heart: what the cardiologist must know

Basic Sciences, Pharmacology, Genomics and Cardiovascular Pathology

 

The great advances in chemotherapy have led to a significant improvement of cancer prognosis but have dramatically increased the incidence of cardiotoxicity.
At present, the secondary effects of cancer therapy that have been shown, of which some are potentially reversible (type II agents – mainly signalling inhibitors), others stable (type I agents – cytotoxic agents) and arising also after many years, are as follows: left ventricular dysfunction, hypertension, arrhythmias (acquired LQTs), myocardial ischemia and thrombotic manifestations.
The aim of this session was to enhance the knowledge of all cardiologists, even if not specifically trained in the field, on the general principle of cardiotoxicity from cancer therapy, the specific clinical implications, and the management criteria.
This could be a difficult task considering the rapidly growing number of new agents used in chemotherapy and the lack of large randomized trials. It is time to simplify the approach to the problem using a schematization of current knowledge, and to permit a rapid update of the new information.
Moreover, it is mandatory to know:

  1. the general principle of evaluation of eligibility of a patient for a specific chemotherapy (risk factors),
  2. what are the necessary useful investigations before, during and after chemotherapy (ECG for rhythm and conduction disturbances and for ischemia signs; Echo or other imaging tests (MRI) to assess left ventricular function at baseline and periodically; biochemical indices such as Troponin or NT-proBNP),
  3. what, if any, are the possible prevention measures against cardiotoxicity (ACE-Inhibitors, BetaBlockers),
  4. what are the follow-up criteria.

References


923

SessionTitle:

Chemotherapy and the heart: what the cardiologist must know

The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.

 

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are